Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Inflamm Bowel Dis. 2011 Jun;17(6):1291-300. doi: 10.1002/ibd.21508. Epub 2010 Oct 25.
Patients with inflammatory bowel disease (IBD) display immunoreactivity to self-antigens and microbial antigens. We used a protein microarray approach to identify novel autoantigens in IBD.
ProtoArray Human Protein Microarray v4.0 containing 8268 human proteins from Invitrogen (La Jolla, CA) was used.
Twenty-five IBD patients and five healthy controls were screened for candidate autoantigens. For 256 antigens, IBD patients had a higher seroreactivity than controls. Twenty antigens were selected for further evaluation in a larger cohort (60 ulcerative colitis [UC] patients, 60 Crohn's disease [CD] patients, 60 healthy controls, and 60 gastrointestinal-diseased controls) by means of a customized protein microarray. Out of these 20 antigens, one antigen, family with sequence similarity 84 member A (FAM84A), was identified as a target antigen in IBD. Antibodies to FAM84A were significantly more prevalent in IBD patients (19%) than in gastrointestinal-diseased controls (1.7%) (P = 0.0008) and healthy controls (5%) (P = 0.01). Anti-FAM84A antibodies were found in 26.6% of UC patients and in 11.7% of CD patients. FAM84A was confirmed as target antigen in IBD by means of Western blotting in a large independent cohort (100 UC patients, 106 CD patients, 102 healthy controls, and 100 gastrointestinal-diseased controls). Antibodies to FAM84A were significantly more prevalent in IBD patients (20%) than in gastrointestinal-diseased controls (5%) (P = 0.0004) and healthy controls (0%) (P < 0.0001). Anti-FAM84A antibodies were found in 18% of UC patients and in 22% of CD patients.
We identified FAM84A as a novel autoantigen in IBD. (Inflamm Bowel Dis 2011;).
炎症性肠病（IBD）患者对自身抗原和微生物抗原表现出免疫反应性。我们使用蛋白质微阵列方法来鉴定 IBD 中的新型自身抗原。
使用 Invitrogen（加利福尼亚州拉霍亚）的 ProtoArray Human Protein Microarray v4.0，其中包含 8268 个人类蛋白。
对 25 名 IBD 患者和 5 名健康对照者进行了候选自身抗原的筛查。对于 256 种抗原，IBD 患者的血清反应性高于对照组。选择了 20 种抗原用于通过定制蛋白质微阵列在更大的队列（60 例溃疡性结肠炎[UC]患者、60 例克罗恩病[CD]患者、60 名健康对照者和 60 名胃肠道疾病对照者）中进行进一步评估。在这 20 种抗原中，一种抗原，家族与序列相似性 84 成员 A（FAM84A），被鉴定为 IBD 的靶抗原。FAM84A 抗体在 IBD 患者（19%）中明显比胃肠道疾病对照者（1.7%）（P=0.0008）和健康对照者（5%）（P=0.01）更为普遍。UC 患者中抗-FAM84A 抗体的发生率为 26.6%，CD 患者中为 11.7%。FAM84A 通过在大型独立队列（100 例 UC 患者、106 例 CD 患者、102 名健康对照者和 100 名胃肠道疾病对照者）中的 Western 印迹得到了确认，作为 IBD 的靶抗原。FAM84A 抗体在 IBD 患者（20%）中明显比胃肠道疾病对照者（5%）（P=0.0004）和健康对照者（0%）（P<0.0001）更为普遍。UC 患者中抗-FAM84A 抗体的发生率为 18%，CD 患者中为 22%。
我们鉴定了 FAM84A 作为 IBD 中的一种新型自身抗原。（炎症性肠病。2011 年）。
